GGrantIndex
← Search

Leadership, Planning and Evaluation

$717,672P30FY2022CANIH

Fred Hutchinson Cancer Center, Seattle WA

Investigators

Linked publications, trials & patents

Trial NCT06995898Trial NCT06682039Trial NCT06484595Trial NCT06193070Trial NCT05947500Trial NCT05930496Trial NCT05183828Trial NCT04902144Trial NCT04751383Trial NCT04682301Trial NCT04667481Trial NCT04660331Trial NCT04539366Trial NCT04505553Trial NCT04502524Trial NCT04500548Trial NCT04496219Trial NCT04489719Trial NCT04472338Trial NCT04466475Trial NCT04447313Trial NCT04444232Trial NCT04442581Trial NCT04431479Trial NCT04410900Trial NCT04387227Trial NCT04384692Trial NCT04383743Trial NCT04375631Trial NCT04372927Trial NCT04370301Trial NCT04359784Trial NCT04336943Trial NCT04329065Trial NCT04282187Trial NCT04260776Trial NCT04257578Trial NCT04254133Trial NCT04231877Trial NCT04220229Trial NCT04211766Trial NCT04208724Trial NCT04205409Trial NCT04200482Trial NCT04198922Trial NCT04196010Trial NCT04195945Trial NCT04195633Trial NCT04194918Trial NCT04188912Trial NCT04175431Trial NCT04156828Trial NCT04155840Trial NCT04151940Trial NCT04120246Trial NCT04111497Trial NCT04083183Trial NCT04083170Trial NCT04081779Trial NCT04081298Trial NCT04062955Trial NCT04060849Trial NCT03999515Trial NCT03991884Trial NCT03986502Trial NCT03980769Trial NCT03970096Trial NCT03907527Trial NCT03891784Trial NCT03864419Trial NCT03807063Trial NCT03806192Trial NCT03781778Trial NCT03779867Trial NCT03779854Trial NCT03778021Trial NCT03776864Trial NCT03749460Trial NCT03747484Trial NCT03737955Trial NCT03723863Trial NCT03718338Trial NCT03672981Trial NCT03670966Trial NCT03670069Trial NCT03660930Trial NCT03649841Trial NCT03641287Trial NCT03606486Trial NCT03602898Trial NCT03600038Trial NCT03585231Trial NCT03574012Trial NCT03570476Trial NCT03531918Trial NCT03525106Trial NCT03523195Trial NCT03522584Trial NCT03518242Trial NCT03516812

Abstract

PROJECT SUMMARY: LEADERSHIP, PLANNING & EVALUATION Dr. Gary Gilliland, the Consortium Director, creates the overarching vision for the Fred Hutch/University of Washington Cancer Consortium. To accomplish this, he engages internal and external leaders, committees, and individuals to help define this vision and to chart the short and long-term steps needed to move towards this goal. Structures have been created to help assure that the plans of the Consortium are congruent with those of the member institutions. With the help of Consortium Administration, methods have been developed to monitor the activities of the Consortium as directed by the planning process and to help assure that these activities are communicated to Consortium members. Robust processes have been created to evaluate progress made in achieving the goals set out in the planning process, report the results of the evaluations back to involved members, review responses to the evaluations, and evaluate the outcomes of those responses. The specific aims for Leadership, Planning & Evaluation are (1) with input from internal and external experts, to identify those areas where investments of time and resources are most likely to assist the Consortium in achieving its mission to eliminate cancer as a cause of suffering and death; (2) to create a structure that engages all Consortium partners in planning so that individual institutional objectives are well aligned with Consortium objectives, (3) to continuously monitor and communicate Consortium activities to all stakeholders, and (4) to create an iterative process for evaluating Consortium activities, providing feedback, reviewing responses to feedback, and revaluating subsequent outcomes.

View original record on NIH RePORTER →